Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 633 of 6351
-
New hope for CLL patients: a drug that may spare the heart
Disease control Recruiting nowThis phase II trial tests how well acalabrutinib works in treating patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and evaluates how treatment with acalabrutinib affects heart function. Acalabrutinib is in a class of medications called kinase inh…
Phase 2 • Sponsor: Seema Bhat • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can a pill prevent eye cancer spread? new trial aims to find out
Prevention Recruiting nowThe purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects that quisinostat has on participants' condition.
Phase 2 • Sponsor: University of Miami • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare muscle disease: drug targets inflammation to preserve walking ability
Disease control Recruiting nowRefer to the "Detailed Description" section.
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for advanced colon cancer: AK112 combo enters phase 3 trial
Disease control Recruiting nowThis trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.
Phase 3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo aims to keep aggressive myeloma at bay
Disease control Recruiting nowThe purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for kids with tough cancers: targeted drug enters trial
Disease control Recruiting nowResearchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very young children * RMS is a cancer that starts in muscle cells, often in a child's …
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Blood test may reveal how well stomach cancer treatment works
Diagnosis Recruiting nowThe primary objective is to determine whether pretreatment-to-posttreatment changes in circulating multigene methylation levels correlate with objective response rates (ORR) assessed by contrast-enhanced CT/MRI and levels of serum tumor markers. Secondary endpoints include: (a) t…
Sponsor: Xijing Hospital • Aim: Diagnosis
Last updated Aug 29, 2026 00:00 UTC
-
Double-Barreled CAR-T cells take aim at Hard-to-Treat myeloma
Disease control Recruiting nowThis is a multicenter, open-label, non-randomized, single-arm clinical trial. Patients with relapsed/refractory multiple myeloma accompanied by extramedullary infiltration will receive BCMA - GPRC5D CAR-T cell therapy. The primary objective is to prospectively evaluate the safet…
Phase 1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug combo aims to boost surgery success in bile duct cancer
Disease control Recruiting nowThe goal of this clinical trial is to learn if Tuvonralimab/Iparomlimab-based neoadjuvant regimens can improve surgical and pathological outcomes in adults (≥18 years) with resectable or borderline-resectable biliary tract cancer (intrahepatic/extrahepatic cholangiocarcinoma or g…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Double-Barreled CAR-T attack on Hard-to-Treat myeloma
Disease control Recruiting nowThis is a multicenter, open-label, non-randomized, single-arm clinical trial. Patients with relapsed/refractory multiple myeloma accompanied by extramedullary infiltration will receive BCMA - CD19 CAR-T cell therapy. The primary objective is to prospectively evaluate the safety …
Phase 1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Magic mushroom therapy could help cancer survivors beat depression
Symptom relief Recruiting nowThis clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: experimental drug combo enters human trials
Disease control By invitation onlyXS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation
Phase 1/2 • Sponsor: NovaOnco Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 12:33 UTC
-
New combo therapy aims to slow head and neck cancer spread
Disease control Recruiting nowThis is a randomized open-label multicentre phase III superiority study of the effect of adding SABR to the standard of care treatment pembrolizumab on progression free survival in patients with oligometastases of a squamous cell carcinoma of the head and neck (SCCHN), histologic…
Phase 3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Could taking a break from hormone therapy be just as good for prostate cancer?
Disease control Recruiting nowThis study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce resource utilization. The primary goal of de-escalati…
Phase 3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 26, 2026 19:20 UTC
-
Blood test may guide cancer care without biopsy
Knowledge-focused Recruiting nowctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer. In certain situations, ctDNA can be used to screen for or detec…
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Mini-Tumors grown in a dish could guide chemo choices for advanced colorectal cancer
Disease control Recruiting nowCOSENSE-1 is an unblinded, phase II, single-armed, single center feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens, for male and female participants aged 18 and older, with microsatellite…
Phase 2 • Sponsor: St. Olavs Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for advanced melanoma: experimental combo enters late-stage trial
Disease control Recruiting nowThe study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Phase 2/3 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could a Triple-Drug combo shrink lung tumors better?
Disease control Recruiting nowThis phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improveme…
Phase 2/3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug D-2570 aims to quiet Flare-Ups in ulcerative colitis
Disease control OngoingThis study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with moderately to severely active ulcerative colitis. A total of 120 subjects are planned to be included.
Phase 2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New antibody drug aims to protect kidneys in PMN patients
Disease control Recruiting nowIn this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infecti…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC